Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-BCMA in Multiple Myeloma
NCT05243212Phase 2Recruiting
- Sponsor
- Sheba Medical Center
- Start
- Sep 2021
- Primary completion
- Sep 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of CAR-BCMA in multiple myeloma (MM) (2 arms), sponsored by Sheba Medical Center. Primary endpoints: Overall Response Rate at 2 months and CAR BCMA related toxicity at 2 years. Started Sep 2021; status: recruiting.
02
Drugs
CAR-BCMA
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05243212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05243212.